Literature DB >> 9918884

Nucleocapsid protein zinc-finger mutants of simian immunodeficiency virus strain mne produce virions that are replication defective in vitro and in vivo.

R J Gorelick1, R E Benveniste, T D Gagliardi, T A Wiltrout, L K Busch, W J Bosche, L V Coren, J D Lifson, P J Bradley, L E Henderson, L O Arthur.   

Abstract

All retroviruses (except the spumaretroviruses) contain a nucleocapsid (NC) protein that encodes one or two copies of the Zn2+-finger sequence -Cys-X2-Cys-X4-His-X4-Cys-. This region has been shown to be essential for recognition and packaging of the genomic RNA during virion particle assembly. Additionally, this region has been shown to be involved in early infection events in a wide spectrum of retroviruses, including mammalian type C [e.g., murine leukemia virus (MuLV)], human immunodeficiency virus type 1 (HIV-1), Rous sarcoma virus, and other retroviruses. Mutations in the two Zn2+-fingers of the NC protein of simian immunodeficiency virus strain Mne [SIV(Mne)] have been generated. The resulting virions contained the normal complement of processed viral proteins with densities indistinguishable from wild-type SIV(Mne). All of the mutants had electron micrograph morphologies similar to those of immature particles observed in wild-type preparations. RNA packaging was less affected by mutations in the NC protein of SIV(Mne) than has been observed for similar mutants in the MuLV and HIV-1 systems. Nevertheless, in vitro replication of SIV(Mne) NC mutants was impaired to levels comparable to those observed for MuLV and HIV-1 NC mutants; replication defective NC mutants are typically 10(5)- to 10(6)-fold less infectious than similar levels of wild-type virus. One mutant, DeltaCys33-Cys36, was also found to be noninfectious in vivo when mutant virus was administered intravenously to a pig-tailed macaque. NC mutations can therefore be used to generate replication defective virions for candidate vaccines in the SIV macaque model for primate lentiviral diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9918884     DOI: 10.1006/viro.1998.9513

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  29 in total

1.  Functional replacement of nucleocapsid flanking regions by heterologous counterparts with divergent primary sequences: effects of chimeric nucleocapsid on the retroviral replication cycle.

Authors:  William Fu; Wei-Shau Hu
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost.

Authors:  R J Gorelick; R E Benveniste; J D Lifson; J L Yovandich; W R Morton; L Kuller; B M Flynn; B A Fisher; J L Rossio; M Piatak; J W Bess; L E Henderson; L O Arthur
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 3.  Nucleocapsid protein function in early infection processes.

Authors:  James A Thomas; Robert J Gorelick
Journal:  Virus Res       Date:  2008-02-14       Impact factor: 3.303

Review 4.  HIV type 1 Gag as a target for antiviral therapy.

Authors:  Abdul A Waheed; Eric O Freed
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-21       Impact factor: 2.205

5.  Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.

Authors:  Wataru Akahata; Zhi-yong Yang; Gary J Nabel
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Elimination of retroviral infectivity by N-ethylmaleimide with preservation of functional envelope glycoproteins.

Authors:  David R Morcock; James A Thomas; Tracy D Gagliardi; Robert J Gorelick; J David Roser; Elena N Chertova; Julian W Bess; David E Ott; Quentin J Sattentau; Ines Frank; Melissa Pope; Jeffrey D Lifson; Louis E Henderson; Bruce J Crise
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

7.  Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.

Authors:  B Poon; J T Safrit; H McClure; C Kitchen; J F Hsu; V Gudeman; C Petropoulos; T Wrin; I S Y Chen; K Grovit-Ferbas
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

8.  Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis.

Authors:  Chi-An Chen; Chih-Ming Ho; Ming-Cheng Chang; Wei-Zun Sun; Yu-Li Chen; Ying-Cheng Chiang; Ming-Hong Syu; Chang-Yao Hsieh; Wen-Fang Cheng
Journal:  Mol Ther       Date:  2010-04-06       Impact factor: 11.454

9.  Functional complementation of nucleocapsid and late domain PTAP mutants of human immunodeficiency virus type 1 during replication.

Authors:  Olga A Nikolaitchik; Robert J Gorelick; Maria G Leavitt; Vinay K Pathak; Wei-Shau Hu
Journal:  Virology       Date:  2008-03-19       Impact factor: 3.616

10.  Human cellular nucleic acid-binding protein Zn2+ fingers support replication of human immunodeficiency virus type 1 when they are substituted in the nucleocapsid protein.

Authors:  Connor F McGrath; James S Buckman; Tracy D Gagliardi; William J Bosche; Lori V Coren; Robert J Gorelick
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.